Bioxytran CCO Mike Sheikh joins Natalie Stoberman from the Proactive newsroom to share the company's progress on its leading drugs candidates ProLectin-M and ProLectin-I.
Bioxytran is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. Leading drug candidates ProLectin-M and ProLectin-I are a new class of antiviral drugs designed to antagonize galectins implicated in viral, inflammatory, fibrotic, and malignant diseases.